【摘要】 胆道系统恶性肿瘤发病率目前有增高趋势,晚期胆道系统恶性肿瘤姑息性化疗效果差,生存期短。白蛋白紫杉醇等新型化疗药物及三药联合化疗方案的探索性治疗提高了晚期胆道系统恶性肿瘤化疗效果。近二十年来,肿瘤基因组分析及分子生物学基础研究进展进一步阐明了其发病机制,且伴随新药研发的不断进步,针对表皮生长因子受体家族靶点、抗血管生成药物靶点、MEK抑制剂、IDH1/2抑制剂及成纤维细胞生长因子受体(FGFR)抑制剂等药物对胆管癌显示了具有一定前景的抗肿瘤活性,部分药物已经获得临床试验成功及适应证批准。化疗及靶向治疗的联合治疗也进行了较多探索。本文就近些年来晚期胆道系统恶性肿瘤的化疗、靶向治疗进展进行综述。更多还原

【Abstract】 The incidence of biliary tract cancer keeps increasing during the past years,the efficacy of palliative chemotherapy is poor and results the short overall survival period.The exploratory treatment of new chemotherapeutics such as albumin paclitaxel and three-drug combination chemotherapy has improved the chemotherapy effect of advanced biliary malignant tumors.In the past two decades,tumor genome analysis and the progress of molecular biology research clarified furtherly its pathogenesis,and with the continuous development of new drugs,those drugs such as EGFR inhibitors,anti-angiogenesis inhibitors,MEK inhibitors,IDH1/2 inhibitors and FGFR inhibitors have shown promising anti-tumor merit against cholangiocarcinoma.Some drugs have been approved for indications.The combination of chemotherapy and targeted therapy has also been explored.This article reviews the progress of chemotherapy and molecular targeting therapy for advanced biliary tract cancer in recent years.更多还原